Nemus Bioscience (NMUS) Stock Price, News & Analysis

Company Overview

Nemus Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics. The company's product candidates in preclinical stage include NB1111 for the treatment of glaucoma; NB1222 used for treating chemotherapy induced nausea and vomiting; and NB3111 for the treatment of methicillin-resistant staphylococcus aureus. Its products under research comprise NB2111 for use in treating chemotherapy induced peripheral neuropathy; and NB2222 for the treatment of uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy. Nemus Bioscience, Inc. has a license agreement with the University of Mississippi to research, develop, and commercialize products for the treatment of infectious diseases. The company was founded in 2012 and is headquartered in Costa Mesa, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 1.00 million shs
• Average Volume: 377,395 shs
• Market Capitalization: $87.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NMUS Stock Analysis - Frequently Asked Questions

How were Nemus Bioscience's earnings last quarter?

Nemus Bioscience Inc (OTCMKTS:NMUS) posted its quarterly earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter.

How do I buy shares of Nemus Bioscience?

Shares of NMUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Nemus Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nemus Bioscience investors own include Canopy Growth (CGC), Emerald Health Therapeutics (EMHTF), MedMen Enterprises (MMNFF), Aurora Cannabis (ACBFF), KushCo (KSHB), 22nd Century Group (XXII) and Cronos Group (CRON).

Company Calendar

• Last Earnings: 5/15/2018
• Today: 5/18/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Cannabis
• Current Symbol: OTCMKTS:NMUS
• CIK: N/A
• Web: www.nemusbioscience.com
• Phone: 949-396-0330
• Fax: N/A
• Employees: 11
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-19,190,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -924.42%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.12
• Quick Ratio: 0.12

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.12) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 133,908,000
• Free Float: N/A
• Market Cap: $87.04 million
• Optionable: Not Optionable
• Beta: -0.04